Novo Nordisk A/S
NOVO-B
Kedudukan dalam Saham
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Harga Saham
$39.33
Modal Pasaran
$173.59B
Perubahan (1 hari)
0.25%
Perubahan (1 tahun)
-26.34%
Negara
DK
Perdagangan Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
Nisbah P/B bagi Novo Nordisk A/S (NOVO-B)
Nisbah P/B pada February 2026 TTM: 7.11
Menurut laporan kewangan dan harga saham terkini Novo Nordisk A/S, nisbah P/B semasa (TTM) ialah 7.11. Pada akhir 2024, nisbah P/B syarikat ialah 19.38.
Sejarah nisbah P/B untuk Novo Nordisk A/S dari 2001 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 7.11 | -4.53% |
| 2025 | 7.45 | -61.56% |
| 2024 | 19.38 | -34.02% |
| 2023 | 29.37 | 15.39% |
| 2022 | 25.45 | 6.65% |
| 2021 | 23.87 | 51.77% |
| 2020 | 15.72 | -1.35% |
| 2019 | 15.94 | 12.22% |
| 2018 | 14.20 | -14.34% |
| 2017 | 16.58 | 16.48% |
| 2016 | 14.23 | -34.97% |
| 2015 | 21.89 | 29.23% |
| 2014 | 16.94 | 35.36% |
| 2013 | 12.51 | -0.67% |
| 2012 | 12.60 | 26.42% |
| 2011 | 9.97 | 0.88% |
| 2010 | 9.88 | 77.44% |
| 2009 | 5.57 | 9.91% |
| 2008 | 5.07 | -20.41% |
| 2007 | 6.36 | 25.26% |
| 2006 | 5.08 | 20.40% |
| 2005 | 4.22 | 11.39% |
| 2004 | 3.79 | 16.59% |
| 2003 | 3.25 | 4.96% |
| 2002 | 3.10 | -47.14% |
| 2001 | 5.86 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 31.9092 | 348.63% |
US
|
|
| 7.3138 | 2.83% |
US
|
|
| -84.6033 | -1,289.48% |
US
|
|
| 8.6873 | 22.14% |
US
|
|
| 8.4776 | 19.19% |
CH
|
